The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN2671137     [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(4...

Synonyms: AC1L9B2S
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C08086


Psychiatry related information on C08086


High impact information on C08086


Chemical compound and disease context of C08086

  • BACKGROUND: Current genotypic algorithms suggest that the HIV-1 protease inhibitors (PI) lopinavir (LPV) and amprenavir (APV) have distinct resistance profiles [11].
  • PATIENTS AND INTERVENTIONS: Patients with HIV-1 RNA > or =500 copies/ml despite > or =20 weeks of treatment with at least one protease inhibitor received abacavir 300 mg twice a day, amprenavir 1200 mg twice a day and efavirenz 600 mg once a day [12].
  • Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir [13].
  • However, TMC114 binding to the MDR HIV-1 protease is reduced by a factor of 13.3, whereas the APV binding constant is reduced only by a factor of 5 [14].
  • The efficacy of an amprenavir (APV)-containing therapy without (group A) or with (group B) ritonavir was assessed in patients with failure of previous protease inhibitor therapy for human immunodeficiency virus (HIV) infection [15].

Biological context of C08086


Anatomical context of C08086


Associations of C08086 with other chemical compounds


Gene context of C08086


Analytical, diagnostic and therapeutic context of C08086


  1. Ligand configurational entropy and protein binding. Chang, C.E., Chen, W., Gilson, M.K. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  2. Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir. Lastere, S., Dalban, C., Collin, G., Descamps, D., Girard, P.M., Clavel, F., Costagliola, D., Brun-Vezinet, F. Antivir. Ther. (Lond.) (2004) [Pubmed]
  3. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Parkin, N.T., Schapiro, J.M. Antivir. Ther. (Lond.) (2004) [Pubmed]
  4. Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics. Jenwitheesuk, E., Samudrala, R. AIDS (2005) [Pubmed]
  5. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. Ziermann, R., Limoli, K., Das, K., Arnold, E., Petropoulos, C.J., Parkin, N.T. J. Virol. (2000) [Pubmed]
  6. Predictors for lower quality of life in the HAART era among HIV-infected men. Liu, C., Johnson, L., Ostrow, D., Silvestre, A., Visscher, B., Jacobson, L.P. J. Acquir. Immune Defic. Syndr. (2006) [Pubmed]
  7. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Masquelier, B., Tamalet, C., Montès, B., Descamps, D., Peytavin, G., Bocket, L., Wirden, M., Izopet, J., Schneider, V., Ferré, V., Ruffault, A., Palmer, P., Trylesinski, A., Miller, M., Brun-Vézinet, F., Costagliola, D. Antivir. Ther. (Lond.) (2004) [Pubmed]
  8. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Lagathu, C., Bastard, J.P., Auclair, M., Maachi, M., Kornprobst, M., Capeau, J., Caron, M. Antivir. Ther. (Lond.) (2004) [Pubmed]
  9. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients. Sabin, C.A., Wilkins, E., Murphy, M., Fisher, M., de Ruiter, A., Easterbrook, P.J., Leen, C., Vlahakis, E., Cane, P.A., Li, X., Pillay, D. Antivir. Ther. (Lond.) (2003) [Pubmed]
  10. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience. Schooley, R.T., Clumeck, N., Haubrich, R., Thompson, M., Danner, S.A., van Der Ende, M.E., Sereni, D., Antunes, F., Blake, D., Myers, R.E., Tisdale, M., Millard, J., Mustafa, N., Nacci, P. Antivir. Ther. (Lond.) (2001) [Pubmed]
  11. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. Parkin, N.T., Chappey, C., Petropoulos, C.J. AIDS (2003) [Pubmed]
  12. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. Falloon, J., Ait-Khaled, M., Thomas, D.A., Brosgart, C.L., Eron Jr, J.J., Feinberg, J., Flanigan, T.P., Hammer, S.M., Kraus, P.W., Murphy, R., Torres, R., Masur, H. AIDS (2002) [Pubmed]
  13. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. Markland, W., Rao, B.G., Parsons, J.D., Black, J., Zuchowski, L., Tisdale, M., Tung, R. J. Virol. (2000) [Pubmed]
  14. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. King, N.M., Prabu-Jeyabalan, M., Nalivaika, E.A., Wigerinck, P., de Béthune, M.P., Schiffer, C.A. J. Virol. (2004) [Pubmed]
  15. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Duval, X., Lamotte, C., Race, E., Descamps, D., Damond, F., Clavel, F., Leport, C., Peytavin, G., Vilde, J.L. Antimicrob. Agents Chemother. (2002) [Pubmed]
  16. Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children. Engelhorn, C., Hoffmann, F., Kurowski, M., Stocker, H., Kruse, G., Notheis, G., Belohradsky, B.H., Wintergerst, U. AIDS (2004) [Pubmed]
  17. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. Gathe, J.C., Ive, P., Wood, R., Schürmann, D., Bellos, N.C., DeJesus, E., Gladysz, A., Garris, C., Yeo, J. AIDS (2004) [Pubmed]
  18. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Tran, J.Q., Petersen, C., Garrett, M., Hee, B., Kerr, B.M. Clin. Pharmacol. Ther. (2002) [Pubmed]
  19. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Wire, M.B., Shelton, M.J., Studenberg, S. Clinical pharmacokinetics. (2006) [Pubmed]
  20. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. Ghosn, J., Chaix, M.L., Peytavin, G., Rey, E., Bresson, J.L., Goujard, C., Katlama, C., Viard, J.P., Tréluyer, J.M., Rouzioux, C. AIDS (2004) [Pubmed]
  21. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Edwards, J.E., Brouwer, K.R., McNamara, P.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  22. Amprenavir. Adkins, J.C., Faulds, D. Drugs (1998) [Pubmed]
  23. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Zhou, H., Gurley, E.C., Jarujaron, S., Ding, H., Fang, Y., Xu, Z., Pandak, W.M., Hylemon, P.B. Am. J. Physiol. Gastrointest. Liver Physiol. (2006) [Pubmed]
  24. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. Vernochet, C., Azoulay, S., Duval, D., Guedj, R., Cottrez, F., Vidal, H., Ailhaud, G., Dani, C. J. Biol. Chem. (2005) [Pubmed]
  25. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. Caron, M., Auclair, M., Sterlingot, H., Kornprobst, M., Capeau, J. AIDS (2003) [Pubmed]
  26. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients. Fätkenheuer, G., Römer, K., Kamps, R., Salzberger, B., Burger, D. AIDS (2001) [Pubmed]
  27. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. Guffanti, M., De Pascalis, C.R., Seminari, E., Fusetti, G., Gianotti, N., Bassetti, D., Galli, A., Castagna, A., Lazzarin, A. AIDS (2003) [Pubmed]
  28. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Arvieux, C., Tribut, O. Drugs (2005) [Pubmed]
  29. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). Gupta, A., Zhang, Y., Unadkat, J.D., Mao, Q. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  30. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Tréluyer, J.M., Bowers, G., Cazali, N., Sonnier, M., Rey, E., Pons, G., Cresteil, T. Drug Metab. Dispos. (2003) [Pubmed]
  31. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Huang, L., Wring, S.A., Woolley, J.L., Brouwer, K.R., Serabjit-Singh, C., Polli, J.W. Drug Metab. Dispos. (2001) [Pubmed]
  32. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Pore, N., Gupta, A.K., Cerniglia, G.J., Maity, A. Neoplasia (2006) [Pubmed]
  33. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier. van der Sandt, I.C., Vos, C.M., Nabulsi, L., Blom-Roosemalen, M.C., Voorwinden, H.H., de Boer, A.G., Breimer, D.D. AIDS (2001) [Pubmed]
  34. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Pellegrin, I., Breilh, D., Coureau, G., Boucher, S., Neau, D., Merel, P., Lacoste, D., Fleury, H., Saux, M.C., Pellegrin, J.L., Lazaro, E., Dabis, F., Thiébaut, R. Antimicrob. Agents Chemother. (2007) [Pubmed]
  35. Amprenavir: a review of its clinical potential in patients with HIV infection. Noble, S., Goa, K.L. Drugs (2000) [Pubmed]
  36. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Polk, R.E., Brophy, D.F., Israel, D.S., Patron, R., Sadler, B.M., Chittick, G.E., Symonds, W.T., Lou, Y., Kristoff, D., Stein, D.S. Antimicrob. Agents Chemother. (2001) [Pubmed]
WikiGenes - Universities